Table 3.

Clinical course and treatment-related morbidity in patients with SSc not responding to autologous SCT

			Anti-double-		Steroid	Karnofsky		Side effects
	Follow-up		stranded DNA:		dosage	score		during
Patient*	(months)	ANA†	ELISA†‡ (iU/ml)	Scl 70†	(mg/day)†§	(%)†	Skin score†	immunoablation
5	13	5120	2.8	+	Refused	60	19	SIRS¶: WHO grade II
Female/23 years/		↓	↓	↓	steroids	↓	↓	Isolated reduction of
1987		2560	None	+		60	19	F VII to 3% (Q 21%)
6	6	5120	None	+	20	70	30	SIRS¶: WHO grade II
Male/25 years/		↓	↓	↓	↓	↓	↓
1995		2560	None	+	20	70	30
7	None	2560	None	+	30	40	32	Fluid retention during
Female/45 years/		↓	↓	↓	↓	↓	↓	preparative regimen
1996		NE	NE	NE	NE	NE	NE

^*Characteristics: sex/age/year of diagnosis. ^† Values above the arrow represent the admission values and those below the arrow represent the present status. ^‡ELISA cut-off was 118 iU/ml. ^§Doses corresponding to prednisolone equivalents. ^¶SIRS due to application of cyclophosphamide and ATG. ELISA, enzyme-linked immunosorbent assay; F VII, blood clotting factor VII; NE, not evaluable; Q, Quick's value (reciprocal value of prothrombin time of the test sample compared with that of normal plasma as percentage); SIRS, systemic inflammatory response syndrome; WHO, World Health Organization.